Drug intelligence / Profile preview

HF158K1

Development stage: Phase 1
Lead developer: HighField Biopharmaceuticals
Modality: Targeted Liposomes → Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

HF158K1 is an investigational liposomal formulation of doxorubicin hydrochloride, encapsulated by lipid membranes containing TL01, a HER2-directed Trastuzumab Fab fragment conjugated lipid. It is designed to bind and deliver doxorubicin to tumor cells, even at low HER2 expression levels. HF158K1 is being developed by HighField Biopharmaceuticals for the treatment of HER2 low and HER2+ advanced solid tumors.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on HF158K1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HF158K1.

Explore the full profile